Identification of Prognostic Biomarkers of Cutaneous Melanoma Based on Analysis of Tumor Mutation Burden

Figure 2

The Kaplan-Meier analysis of TMB and the relationship with clinical risk characteristics. (a) The Kaplan-Meier analysis of patients with low- and high- TMB groups. (b–e) Statistically significant differences () in patients stratified by age, sex, and T and N stages were evidenced by the Wilcox test. TMB: tumor mutation burden.

(a)

(b)

(c)

(d)

(e)